An anonymous director reports

ZYUS LIFE SCIENCES CORPORATION ANNOUNCES CLOSING OF EIGHTH TRANCHE OF SECURED LOAN FINANCING AND AMENDMENT TO UNSECURED PROMISSORY NOTE

Zyus Life Sciences Corp.'s wholly owned subsidiary, Zyus Life Sciences Inc. (Zyus Inc.), has closed an eighth tranche of a secured loan financing on Aug. 13, 2026, with certain lenders, including certain insiders of the company, for gross proceeds of $550,000. The closing of the eighth tranche brings the total amount of the secured loan to $1.67-millin. Zyus Inc. expects to close additional tranches under the secured loan. The aggregate size of the secured loan offering is up to $2-million. Subject to receipt of approval from the TSX Venture Exchange, the secured loan will be secured by a security interest granted under the terms of a general security agreement (subject to an exception in respect of certain assets). The secured loan bears interest at a rate of 12 per cent per annum, payable on maturity, is prepayable by Zyus Inc. at any time without penalty or premium, and will mature six months from the effective date of the loan.

Two of the lenders that participated in the eighth tranche, for an aggregate amount of $250,000, are members of the board of directors of the company. Such participation constitutes a related party transaction as defined under Multilateral Instrument 61-101, Protection of Minority Security Holders in Special Transactions.

The company has relied on the exemption from the valuation requirement pursuant to Section 5.5(b) (Issuer Not Listed on Specified Markets) of MI 61-101 and from the minority shareholder approval requirement prescribed by Section 5.7(1)(a) (Fair Market Value Not More Than 25 Per Cent of Market Capitalization) of MI 61-101. The company did not file a material change report more than 21 days before issuance of the secured loan because the details of the secured loan were not settled until recently.

The company intends to use the net proceeds of the eighth tranche for general working capital purposes. There is no undisclosed material information by the company, and all independent directors have approved the secured loan described in this news release.

Additionally and as previously disclosed by the company in its news release dated March 5, 2026, the company closed an unsecured promissory note debt financing in the principal amount of $500,000 (the March, 2026, promissory note). The March, 2026, promissory note bears interest at a rate of 12 per cent per annum and was originally scheduled to mature on Aug. 5, 2026. On Aug. 5, 2026, the company entered into an agreement with the holder of the March, 2026, promissory note to extend the original maturity date by six months.

The outstanding principal amount of the March, 2026, promissory note is $500,000. Interest will continue to accrue on the outstanding principal amount of the March, 2026, promissory note at a rate of 12 per cent per annum until repayment in accordance with its terms. The amendment to the March, 2026, promissory note was completed to provide near-term liquidity for the company, as required.

About Zyus Life Sciences Corp.

Zyus is a life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management. Through rigorous scientific exploration and clinical research, Zyus aims to secure intellectual property protection, safeguarding its innovative therapies and bolstering shareholder value. Zyus's unwavering commitment extends to obtaining regulatory approval of non-opioid-based pharmaceutical solutions, in pursuit of transformational impact on patients' lives.

We seek Safe Harbor.